Aspivix, the Swiss medtech company behind the innovative Carevix® device, has launched a new crowdfunding campaign on Capital Cell, with a target of €675,545 to accelerate its commercial momentum and strengthen its position in the global women’s health market.to support the next phase of its growth and international expansion. The fundraising initiative follows a period of significant commercial and clinical progress, including the successful launch of Carevix® in the United States and growing adoption across Europe.
The company, now valued at €26’318’642 is transforming gynecological procedures with a modern alternative to the traditional cervical tenaculum, an instrument that has remained largely unchanged for more than two centuries. Using gentle suction rather than sharp hooks, Carevix® is designed to stabilize the cervix while significantly reducing pain and bleeding during procedures such as IUD insertions. Clinical studies have shown reductions of up to 73% in pain and 83% in bleeding, helping improve the experience of women undergoing routine gynecological care.
The new financing round aims to accelerate commercial growth, expand clinical adoption, and support the development of new indications in women’s health and fertility. Aspivix also plans to advance the next generation of its technology while strengthening its international footprint in key markets. Today, Carevix® is FDA-cleared in the United States, CE-marked in Europe, and authorized in several other markets, with commercialization underway in more than a dozen countries.
Aspivix enters this new chapter with strong momentum. The company was named among TIME Magazine’s Best Inventions of 2024, has established strategic collaborations with major women’s health players including Bayer, and continues to generate growing clinical evidence supporting the benefits of its technology. By bringing together investors committed to advancing women’s healthcare, the crowdfunding campaign supports Aspivix’s mission to make gynecological procedures gentler, more accessible, and more patient-centered worldwide.
